Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $642,600.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $21.42, for a total value of $642,600.00. Following the sale, the insider directly owned 59,992 shares of the company’s stock, valued at $1,285,028.64. This represents a 33.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The shares were sold at an average price of $20.22, for a total transaction of $239,505.90.

Monte Rosa Therapeutics Stock Performance

NASDAQ:GLUE opened at $22.28 on Friday. Monte Rosa Therapeutics, Inc. has a 52 week low of $4.12 and a 52 week high of $25.77. The firm’s 50-day simple moving average is $18.96 and its 200 day simple moving average is $18.63. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -15.05 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The company had revenue of $4.21 million for the quarter, compared to the consensus estimate of $10.95 million. Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. Sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Guggenheim decreased their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. upped their target price on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, Wells Fargo & Company cut their price target on Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.50.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC acquired a new position in shares of Monte Rosa Therapeutics during the 4th quarter valued at $30,000. Russell Investments Group Ltd. acquired a new stake in Monte Rosa Therapeutics in the third quarter worth $32,000. Lazard Asset Management LLC increased its stake in Monte Rosa Therapeutics by 42.9% in the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock valued at $48,000 after purchasing an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Monte Rosa Therapeutics by 32.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after purchasing an additional 776 shares during the period. Institutional investors own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.